AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Novonesis AS

Transaction in Own Shares May 23, 2014

3377_dirs_2014-05-23_8c81e5d1-ca12-42ba-bec8-c71e1d1826eb.pdf

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

May 23, 2014

As of May 22, Novozymes has purchased an accumulated 2,582,533 shares with a transaction value of DKK 637.3 million under the stock buyback program Novozymes announced in Company announcement No. 17, 2014 and initiated February 17, 2014. Under the program, Novozymes will buy back B shares worth up to DKK 2 billion in total during 2014.

The following transactions have been made under the program in accordance with the provisions of European Commission Regulation (EC) No. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour Regulation:

Number
of shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 2,427,133 595,491,207
May 16, 2014
May 19, 2014 52,000 268.41 13,957,168
May 20, 2014 36,400 268.67 9,779,484
May 21, 2014 33,000 268.93 8,874,598
May 22, 2014 34,000 271.78 9,240,450
Total accumulated under the program 2,582,533 637,342,907

In addition, transactions necessitated by Novozymes' previously established incentive programs have resulted in a net sale by Novozymes of 10,335 B shares in the period from May 16 to May 22, 2014. The share transactions related to the incentive programs were not part of the Safe Harbour stock buyback program.

Following the transactions stated above, Novozymes owns a total of 6,816,220 treasury shares, corresponding to 2.1% of the stock capital. The total number of shares in the company is 319,700,000, including treasury shares.

Contact information

Investor Relations:
Thomas Bomhoff (DK) +45 3077 1226 [email protected]
Klaus Sindahl (DK) +45 5363 0134 [email protected]
Martin Riise (USA) +1 919 649 2565 [email protected]
Press and media:
Rene Tronborg (DK) +45 3077 2274 [email protected]
Frederik Bjoerndal (Europe) +44 7976138265 [email protected]
Paige Donnelly (USA) +1 919 218 4501 [email protected]
Meng Lian (China) +86 136 9923 1164 [email protected]
Henrique Pellini (Brazil) +55 41 9288 0282 [email protected]
Poonam Kapila (India) +91 991 082 2339 [email protected]

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com

Company announcement No. 42, 2014 Page 1 of 1

Talk to a Data Expert

Have a question? We'll get back to you promptly.